

West Nile Virus (WNV)

NOTE: U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) program oversees the development and licensing of Veterinary Biologics such as vaccines. [This development process](#) is vastly different from human biologics development and takes considerably less time to reach the market.

Development Status

- Discovery, feasibility, and proof of efficacy studies complete.
- Production of Pre-GMP HR-WNV master seed bank in progress.

Technical Summary

WNV together with WEEV and EEEV form a combination vaccine commercially in horses. Current vaccines available to protect against EEEV, WEEV, and West Nile are inactivated (killed) virus vaccines that are relatively ineffective and require multiple injections (as many as three per year) to maintain protection.

Vaccine Name	Manufacturer	Earliest Age	Repeat Dose In	Annual Booster(s)
Equi-Jec 6	Boehringer Ingelheim	4 months	3 to 4 weeks	yes
Equi-Jec 7	Boehringer Ingelheim	4 months	3 to 4 weeks	yes
Equi-Jec WNV	Boehringer Ingelheim	4 months	3 to 4 weeks	yes
Equi-Jec WNV + EWT	Boehringer Ingelheim	4 months	3 to 4 weeks	yes
Prestige 3 + WNV	Merck	6 months	3-4 weeks	yes
Prestige 5 + WNV	Merck	6 months	3-4 weeks	yes
Prestige WNV West Nile Virus	Merck	6 months	3-4 weeks	yes
Vetera EWT + WNV	Boehringer Ingelheim	4 months	3-4 weeks	yes
Vetera Gold XP	Boehringer Ingelheim	4 months	3-4 weeks	yes
Vetera Gold XP + VEE	Boehringer Ingelheim	4 months	3-4 weeks	yes
Vetera VEWT + WNV	Boehringer Ingelheim	4 months	3-4 weeks	yes
Vetera West Nile	Boehringer Ingelheim	4 months	3-4 weeks	yes
West Nile Innovator	Zoetis Animal Health	10 months	3-4 weeks	yes
West Nile Innovator + VEWT	Zoetis Animal Health	10 months	3-4 weeks	yes
West Nile Innovator EWT	Zoetis Animal Health	10 months	3-4 weeks	yes

Vacunax is currently generating EEEV/WEEV & WNV HR transmembrane mutants to identify key sequences for virus attenuation.